IGM Biosciences announced its raised $175 million through the sale of 10.9 million shares at $16 apiece at the launch of its initial public offering Tuesday, much higher than the anticipated $100 million. The preclinical cancer biotech is developing a pipeline based on the use of engineered immunoglobulin M antibodies to fight cancer.
Upsized IPO raises $175M for preclinical biotech IGM Biosciences
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.